Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

erythromycin base (Rx)Brand and Other Names:Ery-Tab, PCE Dispertab

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 250mg
  • 500mg

tablet, delayed-release particles

  • 250mg
  • 333mg
  • 500mg

PCE Dispertab

  • 333mg
  • 500mg

capsule, delayed release particles

  • 250mg
more...

Dose Range

Usual dosage range: 250-500 mg PO q6-12hr or 500 mg q12hr or 333 mg PO q8hr

Severe infections: Up to 4 g/day

Take on empty stomach if possible; PCE Dispertab may be taken with food; base has poorest absorption

Legionnaires Disease

1-4 g/day PO in divided doses for 21 days

Nongonococcal Urethritis

500 mg PO q6hr for 7 days

Bowel Preparation

1 g PO at 1:00, 2:00, and 11:00 PM on day before surgery in combination with PO neomycin and mechanical cleansing of large intestine

Lymphogranuloma Venereum

500 mg PO q6hr for 21 days

Pertussis

500 mg PO q6hr for 14 days

Gastroparesis (Off-label)

250-500 mg PO three times daily before meals

Granuloma Inguinale (Off-label)

500 mg PO four times daily for 21 days

Chancroid (Off-label)

500 mg PO three times daily for 7 days

Dosage Forms & Strengths

tablet

  • 250mg
  • 500mg

tablet, delayed-release particles

  • 250mg
  • 333mg
  • 500mg

PCE Dispertab

  • 333mg
  • 500mg
more...

Dose Range

Mild to moderate infection: 30-50 mg/kg/day PO divided q6-12hr; not to exceed 2 g/day 

Severe infection: 15-50 mg/kg/day PO ; not to exceed 4 g/day

Chalmydial Infection

50 mg/kg/day PO divided q6hr for 14 days 

Pertussis

40-50 mg/kg/day PO divided q6hr for 14 days; not to exceed 2 g/day 

Streptococcal Pharyngitis, Tonsillitis

20 mg/kg/day PO divided q12hr 

Bowel Preparation

20 mg/kg PO at 1:00, 2:00, and 11:00 PM on day before surgery in combination with PO neomycin and mechanical cleansing of large intestine  

Dosing Considerations

Take on empty stomach if possible; PCE Dispertab may be taken with food; base has poorest absorption

Next

Interactions

Interaction Checker

erythromycin base and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Abdominal pain

            Anaphylaxis

            Cholestatic hepatitis

            Confusion

            Diarrhea

            Dyspepsia

            Fever

            Flatulence

            Hallucinations

            Hearing loss

            Headache

            Hypertrophic pyloric stenosis

            Hypotension

            Interstitial nephritis

            Mild allergic reactions

            Nausea

            Nervous system effects, including seizures

            Pain

            Pruritus

            Pseudomembranous colitis

            QT prolongation

            Rash

            Skin eruptions

            Tinnitus

            Torsades de pointes

            Urticaria

            Ventricular arrhythmias

            Ventricular tachycardia

            Vertigo

            Vomiting

            Previous
            Next

            Warnings

            Contraindications

            Documented hypersensitivity

            Coadministration with astemizole, cisapride, lovastatin, simvastatin, or pimozide

            Coadministration with ergotamine or dihydroergotamine (postmarketing reports of acute ergot toxicity characterized by vasospasm and ischemia of extremities and other tissues, including central nervous system [CNS])

            Cautions

            Risk of sudden death from cardiac causes when PO erythromycin used concomitantly with drugs that inhibit CYP3A4

            Erythromycin is considered moderate inhibitor of CYP3A4; may increase toxicity of CYP3A4 substrates

            Colchicine is substrate for both CYP3A4 and efflux transporter P-glycoprotein (P-gp); significant increase in colchicine plasma concentration is anticipated when drug is coadministered with moderate CYP3A4 inhibitors; reduce starting dose of colchicine, and lower maximum colchicine dose

            Caution in liver disease; estolate formulation may cause cholestatic jaundice; gastrointestinal (GI) side effects are common; discontinue if nausea, vomiting, malaise, abdominal colic, or fever occurs

            Caution in ventricular arrhythmias

            Associated with QT prolongation and infrequent cases of arrhythmia

            May increase liver function test values in pregnant women

            GI effects: Abdominal pain and cramping; diarrhea; nausea and vomiting

            Caution in hepatic impairment, history of hepatitis caused by macrolidide, cholestatic hepatitis

            Overgrowth of nonsusceptible bacteria or fungi reported with prolonged use

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: B

            Lactation: Drug enters breast milk; use with caution (American Academy of Pediatrics committee states that drug is compatible with nursing)

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest

            Absorption

            PO absorption is variable but better with salt forms than with base form

            Peak plasma time: Base, 4 hr; ethylsuccinate, 0.5-2.5 hr; delayed with food because of differences in absorption

            Distribution

            Distribution: Crosses placenta; enters breast milk, relative diffusion from blood into CSF: minimal even with inflammation

            Drug crosses placenta and enters breast milk; relative diffusion from blood into cerebrospinal fluid is minimal even with inflammation

            Protein bound: 73-81%

            Metabolism

            Metabolized in liver by CYP3A4

            Enzymes inhibited: CYP1A2, CYP3A4

            Elimination

            Half-life: 1.5-2 hr; 5-6hr (end stage renal disease)

            Excretion: Feces (primarily), urine (2-15% as unchanged drug)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.